Home›Legal›Semaglutide in New York
Semaglutide in New York: Legal Status & Provider Guide (2026)
Quick Answer
Semaglutide is a prescription substance in the United States. Semaglutide is an FDA-approved drug. Compounded versions were temporarily permitted during a drug shortage that ended in early 2025. Current federal law generally prohibits 503A/503B compounding of semaglutide except for narrow clinical exceptions. Patients should verify their provider's legal basis for offering compounded semaglutide. In New York, compounding is governed by the New York State Board of Pharmacy (NYSBP). New York requires a collaborative practice agreement for nurse practitioners prescribing controlled substances, but NPs with full prescriptive authority may prescribe most compounded peptides independently. Physician assistants require physician supervision for prescribing. New York's telehealth prescribing rules require prescribers to hold a New York license; interstate telemedicine prescribing is tightly regulated.
Federal Legal Status
FDA Approval Status
FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy (chronic weight management, 2021), and Rybelsus (oral, type 2 diabetes, 2019). Compounded semaglutide was permitted during shortage but FDA declared shortage resolved in March 2025.
Compounding Pharmacy Rules (Federal)
Compounding of semaglutide was broadly permitted under shortage exemptions through early 2025. Following FDA's March 2025 shortage resolution declaration, 503B outsourcing facilities had a wind-down period through April 2025, and 503A pharmacies through May 2025. As of mid-2025, compounded semaglutide is generally prohibited except for specific patient needs (e.g., documented allergy to an inactive ingredient in the commercially available product) under a valid prescription.
Also Known As
Ozempic · Wegovy · Rybelsus
Primary Research Areas
- Weight management
- Type 2 diabetes
- Cardiovascular risk reduction
- Metabolic health
New York Pharmacy Board & Compounding Rules
Compounding Overview
New York has among the most stringent pharmacy and prescribing regulations in the country. The New York State Board of Pharmacy enforces USP 797 and 795 standards and requires all compounding pharmacies to meet detailed quality and documentation requirements. New York has been particularly active in enforcing against unapproved compounded medications. In-state telehealth peptide providers are subject to strict New York Medical Board oversight.
Notable Rules
- New York requires compounding pharmacies to register separately for sterile compounding.
- The New York Department of Health has enforcement authority over unlicensed pharmaceutical activity.
- New York has stricter-than-federal requirements for documentation of medical necessity for compounded preparations.
- Interstate prescribing into New York requires a New York state license.
- New York and Pennsylvania maintain reciprocal pharmacy licensure recognition for some categories.
Prescribing Requirements in New York
New York requires a collaborative practice agreement for nurse practitioners prescribing controlled substances, but NPs with full prescriptive authority may prescribe most compounded peptides independently. Physician assistants require physician supervision for prescribing. New York's telehealth prescribing rules require prescribers to hold a New York license; interstate telemedicine prescribing is tightly regulated.
About Semaglutide
Semaglutide is a GLP-1 receptor agonist originally developed by Novo Nordisk. It is FDA-approved for type 2 diabetes and chronic weight management and is among the most studied compounds in contemporary metabolic medicine.
For more research information, mechanism of action, and provider availability, see the Semaglutide research profile on PeptideBase.
Frequently Asked Questions
- Is compounded semaglutide legal in 2026?
- FDA declared the semaglutide shortage resolved in March 2025. After wind-down periods, compounding of semaglutide is generally prohibited for 503A and 503B facilities. Narrow exceptions exist for documented allergies to commercially available formulations. Patients should ask providers for the specific legal basis for any compounded product.
- What is the difference between Ozempic, Wegovy, and compounded semaglutide?
- Ozempic (0.5–2 mg weekly injection) is approved for type 2 diabetes. Wegovy (2.4 mg weekly injection) is approved for chronic weight management. Compounded semaglutide was chemically equivalent but manufactured by compounding pharmacies — a practice now restricted following the shortage resolution.
Semaglutide Providers in New York
No providers currently listed in New York for Semaglutide. Browse the full directory to find providers offering Semaglutide.
Browse all Semaglutide providers →Semaglutide Legal Status in Other States
Pharmacy board rules and compounding regulations vary by state. Compare Semaglutide legal status across other major markets:
Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: .